Article ; Online: State of the art and future directions in the systemic treatment of medullary thyroid cancer.
2021 Volume 34, Issue 1, Page(s) 1–8
Abstract: Purpose of review: Systemic treatment is the only therapeutic option for patients with progressive, metastatic medullary thyroid cancer (MTC). Since the discovery of the rearranged during transfection (RET) proto-oncogene (100% hereditary, 60-90% ... ...
Abstract | Purpose of review: Systemic treatment is the only therapeutic option for patients with progressive, metastatic medullary thyroid cancer (MTC). Since the discovery of the rearranged during transfection (RET) proto-oncogene (100% hereditary, 60-90% sporadic MTC), research has focused on finding effective systemic therapies to target this mutation. This review surveys recent findings. Recent findings: Multikinase inhibitors are systemic agents targeting angiogenesis, inhibiting growth of tumor cells and cells in the tumor environment and healthy endothelium. In the phase III EXAM and ZETA trials, cabozantinib and vandetanib showed progression-free survival benefit, without evidence of prolonged overall survival. Selpercatinib and pralsetinib are kinase inhibitors with high specificity for RET; phase I and II studies showed overall response rates of 73% and 71% in first line, and 69% and 60% in second line treatment, respectively. Although resistance mechanisms to mutation-driven therapy will be a challenge in the future, phase III studies are ongoing and neo-adjuvant therapy with selpercatinib is being studied. Summary: The development of selective RET-inhibitors has expanded the therapeutic arsenal to control tumor growth in progressive MTC, with fewer adverse effects than multikinase inhibitors. Future studies should confirm their effectiveness, study neo-adjuvant strategies, and tackle resistance to these inhibitors, ultimately to improve patient outcomes. |
---|---|
MeSH term(s) | Carcinoma, Medullary/congenital ; Carcinoma, Neuroendocrine/drug therapy ; Carcinoma, Neuroendocrine/genetics ; Humans ; Multiple Endocrine Neoplasia Type 2a ; Proto-Oncogene Proteins c-ret/genetics ; Proto-Oncogene Proteins c-ret/therapeutic use ; Thyroid Neoplasms/drug therapy ; Thyroid Neoplasms/genetics |
Chemical Substances | Proto-Oncogene Proteins c-ret (EC 2.7.10.1) |
Language | English |
Publishing date | 2021-10-14 |
Publishing country | United States |
Document type | Journal Article ; Review |
ZDB-ID | 1049384-0 |
ISSN | 1531-703X ; 1040-8746 |
ISSN (online) | 1531-703X |
ISSN | 1040-8746 |
DOI | 10.1097/CCO.0000000000000798 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 3046: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.